Rising Tide Lifts All CAR-T Ships After Gilead/Kite Deal, Kymriah Approval
Excitement around cell therapy has been building in recent years, but companies expect interest to accelerate after Gilead agreed to buy Kite for $11.9bn and Novartis won the first ever CAR-T approval.
